Considering the previous reports [6,28] on the effects of anti-PD-L1 and anti-CTLA-4 mAbs on tumor cell growth, we treated the indicated three different PD-1, PD-L1 and CTLA-4–positive tumor cells for 72 h with 100 nM of PD-L1_1, 10_12, PD-1_1 or ID1 mAbs to compare their biological activity with that of the clinically validated Nivolumab and Ipilimumab mAbs. Here, CTLA4 is linked to neoplasm.